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Abstract: NSCLC accounts for 80% of all cases of lung cancer, which is the leading cause 
of cancer mortality. The majority of NSCLC patients present with advanced, unresectable 
disease, which remains incurable. In advanced disease, chemotherapy with platinum (cis-
platin or carboplatin) in combination with a third-generation cytotoxic drug (vinorelbine, 
gemcitabine, paclitaxel, or docetaxel) can provide a modest improvement in survival without 
impairing quality of life. In chemotherapy-naïve, advanced, non-squamous NSCLC patients, 
the combination of bevacizumab with chemotherapy was shown to produce better outcomes 
than chemotherapy alone. Response rates of 20%–40% can now be expected, with a median 
survival of 8–11 months and a 1-year survival rate of 30%–40%. In second-line treatment, 
docetaxel has shown superiority to best supportive care in terms of survival and quality of life. 
A pooled analysis comparing docetaxel administered weekly versus 3-weekly found similar 
survival rates between the schedules and a non-signiﬁ  cant reduction in febrile neutropenia for 
the weekly regimen. Pemetrexed, a multitargeted antifolate agent, has shown clear activity in 
several tumors, including mesothelioma and NSCLC. In a phase III trial, second-line treatment 
with pemetrexed demonstrated overall survival comparable to docetaxel, with a more manage-
able toxicity proﬁ  le.
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Pemetrexed is a novel antifolate antimetabolite that targets multiple folate-dependent 
enzymatic pathways and inhibits multiple enzymes involved in purine and pyrimi-
dine synthesis (Adjei 2004). In preclinical studies pemetrexed has demonstrated 
antitumor activity in a variety of solid tumor cell lines. Additive or synergic effects 
were obtained when pemetrexed was combined with other cytotoxic agents, includ-
ing cisplatin. Pemetrexed has proven clinical activity in non-small-cell lung cancer 
(NSCLC) patients (Dubey 2005). The contribution of pemetrexed to the treatment of 
NSCLC patients is analyzed in this review.
Pemetrexed in second-line treatment
In a randomized phase III trial the efﬁ  cacy and toxicity of pemetrexed was compared 
to docetaxel in relapsed NSCLC patients (Hanna et al 2004). Until that trial, docetaxel 
was the only approved cytotoxic chemotherapy for second-line NSCLC treatment. 
Eligible patients had a performance status of 0 to 2, previous treatment with one prior 
chemotherapy regimen for advanced disease, and adequate organ function. In this 
non-inferiority study, both pemetrexed and docetaxel were given on day 1 of a 21-day 
cycle. Patients in the pemetrexed arm received folate and B12 supplementation. Five 
hundred and seventy-one eligible patients were randomized to receive either peme-
trexed or docetaxel. Pre-randomization stratiﬁ  cation factors included performance 
status, disease stage, number of previous chemotherapy regimens, response to most Therapeutics and Clinical Risk Management 2008:4(3) 580
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recent chemotherapy, whether the patient had ever received 
either platinum, or paclitaxel therapy, treatment site, and 
baseline homocysteine level. Following disease progression, 
post-study chemotherapy was allowed. The results of this 
study are summarized in Table 1. Response rates were 9.1% 
and 8.8%, and median survival times were 8.3 months and 
7.9 months in the pemetrexed and docetaxel arms, respec-
tively. Median progression-free survival was 2.9 months 
for each arm and the 1-year survival rate for each arm was 
29.7%. The docetaxel arm had higher incidence of grade 3/4 
neutropenia (40% vs 5%), neutropenic fever (13% vs 2%), 
and neuropathy (8% vs 3%) than the pemetrexed arm. Thus, 
pemetrexed produced similar results and was better tolerated 
than docetaxel in the treatment of pretreated NSCLC patients 
(Cohen 2005).
Weiss et al performed a subset analysis of the above 
randomized phase III trial of pemetrexed vs docetaxel to 
analyze whether the elderly population beneﬁ  ts from second-
line cytotoxic chemotherapy (Weiss et al 2006). Eighty-six 
of 571 patients (15%) were 70 years old, similar to rates 
of elderly observed in the ﬁ  rst-line setting. Elderly patients 
receiving pemetrexed (n = 47) or docetaxel (n = 39) had a 
median survival of 9.5 months and 7.7 months compared with 
7.8 months and 8.0 months for younger patients receiving 
pemetrexed (n = 236) or docetaxel (n = 249), respectively. 
Elderly patients treated with pemetrexed had a longer time 
to progression and a longer survival than their counterparts 
treated with docetaxel (not statistically signiﬁ  cant). Febrile 
neutropenia was less frequent in the elderly patients treated 
with pemetrexed (2.5%) than in those receiving docetaxel 
(19%; p = 0.025).
Pujol et al performed a retrospective risk-beneﬁ  t analy-
sis of survival without grade 3–4 toxicity, deﬁ  ned as the 
time to the ﬁ  rst occurrence of Common Toxicity Criteria 
grade 3 or 4 toxicity or death, in the above prospective 
phase III study comparing pemetrexed with docetaxel (Pujol 
et al 2007). In this analysis, pemetrexed demonstrated a 
statistically signiﬁ  cant longer survival without grade 3/4 
toxicity compared with docetaxel (HR 0.60; p  0.0001). 
A supportive analysis based on selected grade 3/4 toxicities 
(neutropenia lasting 5 days, febrile neutropenia, infec-
tion with neutropenia, anemia, thrombocytopenia, fatigue, 
nausea, vomiting, diarrhea, stomatitis, and neurosensory 
events) also demonstrated an advantage for pemetrexed (HR 
0.53; p  0.0001). This analysis of survival without grade 
3/4 toxicities suggests a beneﬁ  t-to-risk proﬁ  le that favors 
pemetrexed over decetaxel in the second-line treatment of 
NSCLC patients.
In another subset analysis, the investigators evaluated 
the impact of ﬁ  rst-line chemotherapy on the outcome of 
second-line chemotherapy (Weiss et al 2007a). Compari-
sons were made based on type of ﬁ  rst-line chemotherapy 
(gemcitabine/platinum, taxane/platinum, or others), response 
to initial therapy, and clinical characteristics. By multivariate 
analysis, gender, stage at diagnosis, performance status, and 
best response to ﬁ  rst-line therapy signiﬁ  cantly inﬂ  uenced 
overall survival.
The activity and toxicity of pemetrexed has been evalu-
ated in a post-registration study in routine clinical practice 
(Bearz et al 2007). One hundred and sixty patients from 4 
different Italian institutions, treated with pemetrexed, mostly 
as second-line therapy, were analyzed. There was a predomi-
nance of males, adenocarcinoma, and the median age was 
63.6 years. Toxicity was mild, the response rate was 11.2%, 
and median survival was 12 months.
During the 2007 ASCO meeting, Cullen et al presented 
a study in which they compared a high dose of pemetrexed 
(900 mg/m2) with the standard dose (500 mg/m2), each given 
once every 21 days, in advanced NSCLC patients with disease 
progression after treatment with a platinum-containing regi-
men (Cullen et al 2007). The primary objective of this study 
was survival. In this trial, 629 patients were accrued, of which 
588 were eligible for inclusion, 295 received the standard 
pemetrexed dose and 293 received the higher pemetrexed 
dose. No differences were detected between the high dose 
and the standard dose of pemetrexed in terms of survival, 
progression-free survival or response rate. Overall survival 
in the two arms was equivalent (median survival of standard 
dose of 6.7 months compared with 6.9 months for patients 
who received the higher dose). The efﬁ  cacy results of this 
study are summarized in Table 2. Patients in the higher dose 
arm had slightly higher toxicity. In a similar Japanese study, 
244 patients with prior chemotherapy were randomized to 
Table 1 Efﬁ  cacy results of the phase III second-line trial comparing 
pemetrexed with docetaxel
  Pemetrexed  Docetaxel  HR; p value
 N  = 283 N  = 288
Median overall  8.3 months  7.9 months  HR = 0.99
survival    P  0.93
1-year survival rate  29.7%  29.7%  –
Median 2.9  months  2.9  months  –
progression-free
survival
Time to   3.4 months  3.5 months  –
progressive-disease
Overall response rate  9.1%  8.8%  –Therapeutics and Clinical Risk Management 2008:4(3) 581
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receive pemetrexed 500 mg/m2 or pemetrexed 1000 mg/m2 
(Ichinose et al 2007). Overall response rate was 18% for the 
standard pemetrexed dose and 15% for the high pemetrexed 
dose. Median progression-free survival was 3.0 months for 
the standard pemetrexed dose and 2.4 months for the high 
pemetrexed dose. Thus, the standard pemetrexed dose in 
second-line therapy should remain at 500 mg/m2.
Pemetrexed in combination 
in NSCLC
The combination of pemetrexed/carboplatin has been 
analyzed in several trials. In the study of Zinner et al 55 
patients received carboplatin (AUC = 6) and pemetrexed 
500 mg/m2 day 1 every 3 weeks (Zinner et al 2005). The 
response rate was 24%, median time to progression was 
5.4 months, 1-year survival 56%, and median survival 13.5 
months. This was a very well-tolerated regimen. Peme-
trexed and gemcitabine have demonstrated independent 
anti-tumor activity in patients with advanced NSCLC. In 
a phase II study, 53 chemotherapy-naïve advanced NSCLC 
patients received pemetrexed immediately after gem-
citabine in day 1 (Treat et al 2006). Best tumor response 
consisted of 1 patient with complete response (2.0%), 
15 with partial response (30.6%), 17 with stable disease 
(34.7%), and 16 with progressive disease (32.7%). Median 
time to disease progression was 3.3 months and median 
survival was 10.3 months.
In a phase I/II study of pemetrexed/vinorelbine in 
combination, the authors investigated the usefulness of 
plasma pharmacokinetic and pharmacodynamic measures in 
understanding the time course and extent of the inhibition of 
thymidylate synthase by pemetrexed (Li et al 2007). Eighteen 
patients received folic acid and vitamin B12 supplements 
1 week before beginning pemetrexed/vinorelbine treatment. 
Blood samples were collected in the ﬁ  rst cycle for pharma-
cokinetic analyses and in the ﬁ  rst two cycles for determina-
tion of plasma thymidine, deoxyuridine, homocysteine and 
methylmalonic acid concentrations. The results of this study 
suggest that the thymidylate synthase inhibitory effects of 
pemetrexed are short-lived and make the case for a more 
frequent schedule of administration, such as every 2 weeks. 
Baseline homocysteine concentration remains a predic-
tive marker for hematologic toxicity even following folate 
supplementation.
Pemetrexed has also been combined with bevacizumab. 
In a multicenter phase II study the researchers evaluated the 
safety of combining bevacizumab with either chemotherapy 
(pemetrexed or docetaxel) or erlotinib (Herbst et al 2007). 
One hundred and twenty patients were randomly assigned 
and treated. The risk of disease progression or death was 
0.66 among patients treated with bevacizumab/chemotherapy 
and 0.72 among patients treated with bevacizumab/erlotinib 
when compared to those treated with chemotherapy alone, 
although the differences were not statistically signiﬁ  cant. 
One-year survival rate was 57.4% for bevacizumab/erlotinib 
and 53.8% for bevacizumab/chemotherapy compared with 
33.1% for chemotherapy alone. The conclusion of this study 
was that progression-free survival favored bevacizumab in 
combination with either chemotherapy or erlotinib over che-
motherapy alone in the second-line setting. No unexpected 
toxicities were noted.
In a single-institution experience, patients with advanced 
NSCLC with progression following ﬁ  rst-line therapy and 
who received either pemetrexed alone or pemetrexed/beva-
cizumab were analyzed (Weiss et al 2007b). Twenty-ﬁ  ve 
patients were treated with pemetrexed or pemetrexed/
bevacizumab. After a median follow-up of 9.3 months, no 
differences were observed between the cohorts for median 
overall survival, time to progression, or disease control rate. 
There were no grade 3–5 hemorrhagic events. In this retro-
spective single institution analysis, the authors concluded 
that pemetrexed/bevacizumab was safely administered in 
the salvage setting of advanced disease. Whether bevaci-
zumab enhances the efﬁ  cacy of pemetrexed remains to be 
determined and is the subject of an ongoing randomized 
clinical trial.
The combination of pemetrexed with other targeted 
agents has been tested in NSCLC clinical trials. Pemetrexed/
vandetanib (ZD6474) combination has been analyzed in 
a phase I trial in previously treated NSCLC patients (De 
Boer et al 2007). Pemetrexed/vandetanib was generally well 
tolerated, with no apparent PK interaction. In 18 patients 
evaluable for efﬁ  cacy, one had partial response and 13 
patients had stable disease. A phase III trial of pemetrexed/
vandetanib 100 mg in second-line NSCLC has begun. 
Table 2 Pemetrexed 500 mg/m2 vs 900 mg/m2 in second-line 
NSCLC treatment – efﬁ  cacy results
  Pemetrexed Pemetrexed Statistical
 500  mg/m2  900 mg/m2  values
 N  = 295 N  = 293 
Median survival  6.7 months  6.9 months  HR = 1.01
Progression-free  2.6 months  2.8 months  HR = 0.97
survival
Overall response   7.1%  4.3%  P = 0.1616
rateTherapeutics and Clinical Risk Management 2008:4(3) 582
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A phase I-IIa study evaluated the feasibility of combining 
pemetrexed/cetuximab in patients with recurrent NSCLC 
(Jalal et al 2007). In this study it was found feasible and 
safe to combine pemetrexed at 750 mg/m2 every 21 days 
and cetuximab at 400 mg/m2 week 1 and 250 mg/m2 weekly 
thereafter. Response data were available for 18 patients, 
with partial response in 2 patients (9%) and stable disease 
in 8 patients (35%).
Pemetrexed in ﬁ  rst-line treatment 
of advanced NSCLC
In a multicenter phase II trial, the investigators determined 
the efﬁ  cacy and toxicity of two pemetrexed-based regimens 
in chemotherapy-naïve patients with advanced NSCLC 
(Scagliotti et al 2005a). Forty-one patients received peme-
trexed/oxaliplatin and 39 received pemetrexed/carboplatin. 
Objective response rates were 26.8% for pemetrexed/oxali-
platin patients and 31.6% for pemetrexed/carboplatin 
patients. Median time to progression was 5.5 and 5.7 months 
for pemetrexed/oxaliplatin and pemetrexed/carboplatin, 
respectively. Median overall survival was 10.5 months 
for both treatment groups. The 1-year survival rate was 
49.9% for pemetrexed/oxaliplatin patients and 43.9% for 
pemetrexed/carboplatin. Hematologic toxicities among 
pemetrexed/oxaliplatin-treated patients were grade 3/4 
neutropenia (7.3%), grade 3 thrombocytopenia (2.4%), and 
grade 3 anemia (7.3%). Pemetrexed/carboplatin-treated 
patients experienced grade 3/4 neutropenia (25.6%), grade 
3/4 thrombocytopenia (17.9%), and grade 3 anemia (7.7%). 
Three patients had febrile neutropenia (pemetrexed/oxali-
platin 1 and pemetrexed/carboplatin 2).
In a randomized phase II trial single agent pemetrexed 
or sequential pemetrexed/gemcitabine was evaluated in 
chemotherapy-naïve patients with NSCLC who were 
elderly (70 years) or younger than 70 years and ineligible 
for platinum-based chemotherapy (Gridelli et al 2007). 
Eighty-seven patients received treatment (44 pemetrexed; 
43 pemetrexed/gemcitabine). The median time to pro-
gression was 4.5 and 4.1 months for the pemetrexed and 
pemetrexed/gemcitabine arms, respectively, and the median 
progression-free survival time was 3.3 months for both arms. 
Tumor response rates for the pemetrexed and pemetrexed/
gemcitabine arms were 4.5% and 11.6%, respectively. The 
median overall survival time was 4.7 months for the peme-
trexed arm and 5.4 months for the pemetrexed/gemcitabine 
arm, with respective 1-year survival rates of 28.5% and 
28.1%. Grade 3/4 hematologic toxicity consisted of neutro-
penia (4.5% pemetrexed; 4.7% pemetrexed/gemcitabine), 
thrombocytopenia (4.5% pemetrexed; 7.0% pemetrexed/
gemcitabine), and anemia (6.8% pemetrexed; 4.7% 
pemetrexed/gemcitabine). No grade 3/4 nonhematologic 
toxicities exceeded 4.7% in either arm. The conclusion of 
this phase II trial is that single-agent pemetrexed and sequen-
tial pemetrexed/gemcitabine have shown moderate activity 
and are well tolerated as ﬁ  rst-line treatment for advanced 
NSCLC in elderly patients or those deemed unsuitable for 
platinum-based combination chemotherapy.
During the ASCO 2007 meeting, the Norwegian Lung 
Cancer Group presented a phase III trial comparing peme-
trexed (500 mg/m2 on day 1) or gemcitabine (1000 mg/m2 on 
days 1 and 8) in combination with carboplatin (AUC = 5 on 
day 1) as ﬁ  rst-line therapy for patients with advanced NSCLC 
(Gronberg et al 2007). Each regimen was administered every 
3 weeks. A total of 446 patients were included; 219 received 
pemetrexed/carboplatin and 218 gemcitabine/carboplatin. 
Mean quality of life scores were stable throughout the study 
period, and no signiﬁ  cant differences were noted between the 
treatment arms. However, there were signiﬁ  cant differences 
in toxicity, with patients in the gemcitabine arm experiencing 
more grade 3 and 4 leukopenia and thrombocytopenia. There 
was no difference in overall survival for patients in the two 
arms; median survival for patients receiving pemetrexed was 
7.3 months compared with 7.0 months for patients receiving 
gemcitabine.
During the 12th World Conference on Lung Cancer, 
Scagliotti et al presented the results of a phase III study of 
pemetrexed/cisplatin vs gemcitabine/cisplatin in chemo-
therapy-naïve patients with locally advanced or metastatic 
NSCLC (Scagliotti et al 2007b). ECOG PS 0–1 patients 
were randomized to receive cisplatin 75 mg/m2 day 1 with 
pemetrexed 500 mg/m2 day 1 or gemcitabine 1250 mg/m2 
day 1, 8 with cisplatin 75 mg/m2 day 1, every 3 weeks. Both 
arms received folic acid, vitamin B12, and dexamethasone. 
The primary endpoint of this non-inferiority study was 
overall survival. From July 2004 to December 2005, 1725 
patients were randomized. Overall survival for patients 
randomized to pemetrexed/cisplatin was non-inferior to 
gemcitabine/cisplatin (10.3 vs 10.3 months; HR = 0.94). 
Similarly, progression-free survival and response rate 
showed non-inferiority for pemetrexed/cisplatin vs gem-
citabine/cisplatin. Hematologic grade 3/4 toxicities were 
statistically signiﬁ  cantly lower for pemetrexed/cisplatin. 
Less grade 3/4 nausea and anorexia were observed for 
gemcitabine/cisplatin. In a pre-speciﬁ  ed analysis by histo-
logic groups, pemetrexed/cisplatin had signiﬁ  cantly better 
survival than gemcitabine/cisplatin in the adenocarcinoma Therapeutics and Clinical Risk Management 2008:4(3) 583
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group (N = 847; 12.6 vs 10.9 months; HR = 0.84) and 
in large cell histology (N = 153; 10.4 vs 6.7 months; 
HR = 0.68). In contrast, there was a non-signiﬁ  cant trend 
toward better survival with gemcitabine/cisplatin in squamous 
cell histology (N = 473; 9.4 vs 10.8 months; HR = 1.22).
Pemetrexed in combination 
with thoracic radiotherapy in 
unresectable stage III NSCLC
In a phase I trial, the maximum tolerated dose for peme-
trexed alone and in combination with carboplatin plus 
concurrent radiotherapy was determined (Seiwert et al 
2007). Patients with advanced NSCLC or esophageal can-
cer were given two cycles with a 21-day interval. Patients 
received either pemetrexed or pemetrexed/carboplatin, both 
with concurrent radiation. In this study the combination of 
pemetrexed (500 mg/m2) and carboplatin (AUC = 5 or 6) 
with concurrent radiation was well tolerated, allowed for the 
administration of systemically active chemotherapy doses 
and showed signs of activity. A phase I study of concurrent 
pemetrexed/cisplatin and concurrent thoracic radiotherapy 
(61–66 Gy) in unresectable stage IIIA/B patients has been 
recently carried out (Brade et al 2007). In this study, full 
dose pemetrexed and cisplatin given concurrently with full 
dose radiotherapy was well tolerated and a phase II study 
is planned.
Pemetrexed in early-stage NSCLC
About 30% of NSCLC patients are diagnosed with early-
stage of disease. Adjuvant chemotherapy has been proven to 
be beneﬁ  cial for certain patients with resected NSCLC. The 
majority of patients in the adjuvant treatment setting receive 
a combination of cisplatin/vinorelbine. However, toxicity 
and insufﬁ  cient dose delivery have been critical issues. The 
combination of cisplatin/vinorelbine has resulted in rates of 
grade 3/4 neutropenia of around 75% and rates of febrile 
neutropenia of up to 12%. In the TREAT phase II study 
(“Trial of Reﬁ  nement of Early stage NSCLC. Adjuvant che-
motherapy with pemetrexed and cisplatin vs vinorelbine and 
cisplatin”), patients with pathologically stage IB, II, T3N1, 
and complete surgical resection are randomized to receive 
either 4 cycles of adjuvant vinorelbine/cisplatin, or 4 cycles 
of pemetrexed 500 mg/m2 day 1 and cisplatin 75 mg/m2 day 
1 every 3 weeks (Kreuter et al 2007). The primary objective 
is to compare clinical feasibility of these cisplatin doublets 
deﬁ  ned as non-occurrence of grade 4 neutropenia and/or 
thrombocytopenia for 7 days or bleeding, grade 3/4 febrile 
neutropenia and/or infection, grade 3/4 non-hematological 
toxicity, non-acceptance leading to premature withdrawal, 
and no cancer or therapy-related death. Secondary param-
eters are efﬁ  cacy (time to relapse, overall survival) and drug 
delivery. The hypothesis of the study is that reduced toxicity 
will improve the feasibility of drug delivery, compliance, and 
the convenience of treatment for the patients. In this study a 
total of 134 patients are planned.
Pharmacogenomic assessment
A crucial aspect of the clinical development of new drugs 
is to understand which patients will reap clinical beneﬁ  t 
from their use (Rosell et al 2004a). The clinical applica-
tion of mRNA expression levels of ampliﬁ  ed genes may 
disclose extensive genetic impact on cytotoxic drug sensi-
tivity and enable clinicians to tailor chemotherapy to each 
individual’s genetic proﬁ  le. The assessment of thymidilate 
synthase mRNA expression levels might prove useful to 
select patients who will beneﬁ  t from pemetrexed (Rosell 
et al 2004b).
Scagliotti et al quantiﬁ  ed mRNA and protein levels in 
pretreatment biopsies of patients included in the previously 
mentioned phase III trial comparing pemetrexed/cisplatin 
with gemcitabine/cisplatin in order to identify biomarkers 
that may predict clinical outcome (Scagliotti et al 2007c). 
Of 232 patients with tissue samples, 69 had gene expression 
results and 181 had immunohistochemistry results. High 
EGFR expression was associated with improved clinical 
outcome irrespective of treatment arm; high EGFR was 
associated with improved progression-free survival and time 
to progression regardless of treatment arm. A statistically 
signiﬁ  cant interaction between thymidylate synthase and 
treatment effect was observed for time to disease progres-
sion. The results of this subset analysis suggest a potential 
association between low thymidylate synthase expression 
and improved outcome with pemetrexed/cisplatin.
In a retrospective analysis of the phase III study com-
paring pemetrexed versus docetaxel in second-line setting, 
the authors presented the ﬁ  nding that docetaxel had statisti-
cally better survival than pemetrexed in the squamous cell 
subgroup, while pemetrexed had statistically better survival 
than docetaxel in the combined non-squamous subgroup 
(Peterson et al 2007). These results agree with those reported 
in the ﬁ  rst-line study comparing cisplatin/gemcitabine with 
cisplatin/pemetrexed mentioned earlier. A further study indi-
cated higher thymidylate synthase expression in squamous 
cell carcinoma than in adenocarcinoma. One hypothesis is 
that thymidylate synthase overexpression in squamous cell Therapeutics and Clinical Risk Management 2008:4(3) 584
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carcinoma leads to reduce pemetrexed sensitivity. Larger 
translational research studies to determine the prognostic 
and predictive value of biomarkers in pemetrexed-treated 
patients are required.
Hsu et al used a genomic strategy to develop signatures 
predictive of chemotherapeutic response to both cisplatin and 
pemetrexed (Hsu et al 2007). Using in vitro drug sensitivity 
data, coupled with microarray data, the investigators devel-
oped gene expression signatures predicting sensitivity to 
cisplatin and pemetrexed. Signatures were validated with 
response data from 32 independent ovarian and lung cancer 
cell lines as well as 59 samples from patients previously 
treated with cisplatin. In this experience, genomic-derived 
signatures of cisplatin and pemetrexed sensitivity were shown 
to accurately predict sensitivity in vitro and, in the case of 
cisplatin, to predict treatment response in patients treated 
with cisplatin. Interestingly, an inverse correlation was seen 
between in vitro cisplatin and pemetrexed sensitivity, and 
between the likelihood of cisplatin and pemetrexed response 
in patients. The conclusion of the authors is that the use of 
genomic predictors of response to cisplatin and pemetrexed 
can be incorporated into strategies to optimize therapy in 
advanced solid tumors.
Summary
Pemetrexed is a novel antimetabolite with inhibitory activity 
against a number of folate-dependent enzymes. As second-line 
treatment for advanced NSCLC, pemetrexed, when administered 
with folic acid and vitamin B12, has demonstrated comparable 
efﬁ  cacy and a better toxicity proﬁ  le relative to docetaxel. In 
ﬁ  rst-line treatment pemetrexed in combination with cisplatin 
produces equivalent response and overall survival compared to a 
combination of cisplatin/gemcitabine. The role of targeted agents 
in combination with pemetrexed as well as pharmacogenomic 
approaches is, at present, being evaluated in NSCLC patients.
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